Next Article in Journal
TRIM19/PML Restricts HIV Infection in a Cell Type-Dependent Manner
Next Article in Special Issue
Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
Previous Article in Journal
Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material
Previous Article in Special Issue
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Article Menu

Export Article

Open AccessArticle

Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma

Faculty of Veterinary Medicine and Animal Husbandry, National Autonomous University of Mexico, Mexico City 04510, Mexico
Medical Research Unit, Oncology Hospital, Mexican Institute for Social Security, Mexico City 06720, Mexico
Biomedical Cancer Research Unit, National Cancer Institute and Physics Institute, National Autonomous University of Mexico, Mexico City 14080, Mexico
Pathology Department, Spanish Hospital, Mexico City 11520, Mexico
Hematology Department, National Cancer Institute, Mexico City 14080, Mexico
Authors to whom correspondence should be addressed.
Academic Editors: E. Antonio Chiocca and Martine L. M. Lamfers
Viruses 2016, 8(1), 3;
Received: 1 September 2015 / Revised: 17 November 2015 / Accepted: 24 November 2015 / Published: 23 December 2015
(This article belongs to the Special Issue Oncolytic Viruses)
PDF [4814 KB, uploaded 23 December 2015]


Research on oncolytic viruses has mostly been directed towards the treatment of solid tumors, which has yielded limited information regarding their activity in hematological cancer. It has also been directed towards the treatment of humans, yet veterinary medicine may also benefit. Several strains of the Newcastle disease virus (NDV) have been used as oncolytics in vitro and in a number of in vivo experiments. We studied the cytolytic effect of NDV-MLS, a low virulence attenuated lentogenic strain, on a human large B-cell lymphoma cell line (SU-DHL-4), as well as on primary canine-derived B-cell lymphoma cells, and compared them to healthy peripheral blood mononuclear cells (PBMC) from both humans and dogs. NDV-MLS reduced cell survival in both human (42% ± 5%) and dog (34% ± 12%) lymphoma cells as compared to untreated controls. No significant effect on PBMC was seen. Cell death involved apoptosis as documented by flow-cytometry. NDV-MLS infections of malignant lymphoma tumors in vivo in dogs were confirmed by electron microscopy. Early (24 h) biodistribution of intravenous injection of 1 × 1012 TCID50 (tissue culture infective dose) in a dog with T-cell lymphoma showed viral localization only in the kidney, the salivary gland, the lung and the stomach by immunohistochemistry and/or endpoint PCR. We conclude that NDV-MLS may be a promising agent for the treatment of lymphomas. Future research is needed to elucidate the optimal therapeutic regimen and establish appropriate biosafety measures. View Full-Text
Keywords: Newcastle disease virus; lymphoma; oncolytic virus Newcastle disease virus; lymphoma; oncolytic virus

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Sánchez, D.; Pelayo, R.; Medina, L.A.; Vadillo, E.; Sánchez, R.; Núñez, L.; Cesarman-Maus, G.; Sarmiento-Silva, R.E. Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. Viruses 2016, 8, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top